Latest News

Ampio Announces Investor Call on Thursday, July 16, 4:30 p.m. EDT

Date: July 9, 2015 | READ MORE >

Ampio Pharmaceuticals Announces Additional Statistically Significant Study Results for Optina™ in the Treatment of Diabetic Macular Edema (DME)

Date: June 22, 2015 | READ MORE >

Ampio Pharmaceuticals Provides Information on the Formation and Significance of Aytu BioScience to Ampio Shareholders

Date: June 16, 2015 | READ MORE >

Ampio Pharmaceuticals Reports the Synergistic Effects of Ampion in the Treatment of Osteoarthritis of the Knee in Three Peer-reviewed Publications

Date: June 9, 2015 | READ MORE >

Ampio Pharmaceuticals Announces Update of STRIDE Study for the Investigation of Pain Associated with Osteoarthritis

Date: June 4, 2015 | READ MORE >

Ampio Pharmaceuticals Announces Positive Study Results on Optina for the Treatment of Diabetic Macular Edema

Date: May 21, 2015 | READ MORE >

Ampio Announces Top-Line Results of the Double-Blind Multiple Intra-Articular Injections (STRUT) Study of Ampion™ in Patients with Moderate to Severe Osteoarthritis of the Knee

Date: February 25, 2015 | READ MORE >

Ampio Updates Status of Clinical Trials and Manufacturing Facility

Date: November 12, 2014 | READ MORE >

Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facility

Date: July 30, 2014 | READ MORE >

Ampio Receives FDA Confirmation that The Spring Study is Pivotal and Will Initiate the Final Pivotal Trial for Ampion™ Biological License Application (BLA)

Date: December 2, 2013 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial

Date: August 14, 2013 | READ MORE >